United Capital Financial Advisors LLC purchased a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 24,033 shares of the medical technology company's stock, valued at approximately $7,567,000.
Other large investors have also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Stryker during the fourth quarter worth about $1,822,272,000. Bank of America Corp DE purchased a new stake in shares of Stryker during the 2nd quarter worth about $1,404,284,000. Auto Owners Insurance Co increased its position in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares in the last quarter. Legal & General Group Plc acquired a new stake in Stryker in the 2nd quarter valued at $707,212,000. Finally, Jupiter Topco LLC purchased a new position in Stryker in the 2nd quarter worth approximately $681,581,000. Institutional investors and hedge funds own 77.09% of the company's stock.
Insider Activity
In other news, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company's stock.
Stryker Price Performance
NYSE SYK opened at $322.20 on Friday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $123.58 billion, a PE ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a 50 day moving average price of $328.64 and a two-hundred day moving average price of $331.47.
Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the firm earned $3.13 EPS. Stryker's quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.
Wall Street Analyst Weigh In
SYK has been the topic of a number of recent analyst reports. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research report on Friday, June 5th. Wells Fargo & Company dropped their price target on Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 target price for the company. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Finally, Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $386.28.
Read Our Latest Stock Report on Stryker
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
